BI-1206

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBI-1206
Drug Alias Name6G-11BI-1206
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b antagonists
TargetsLow affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsSolid tumoursWaldenstrom MacroglobulinemiaLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenPoland +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBioinvent International Ab
China Registration ClassN/A

Develop Information

Active CompaniesKaixin Pharmaceuticals IncBioinvent International AbCasi Pharmaceuticals Inc +[4] 
Inactive CompaniesCancer Research UK
Active IndicationsSolid tumoursLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsWaldenstrom MacroglobulinemiaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A